drugset / Trial / NCT03526042
Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis
Unknown
40 enrolled
National Institute of Medical Sciences and Nutrition Salvador Zubiran
National Council of Science and Technology, Mexico · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
Antibodies directed against angiotensin-II receptor (AT1-Ab) are agonist antibodies previously studied in human diseases such as preeclampsia, transplantation and scleroderma. They act by binding to the AT1 receptor and their effects can be blocked with the use of angiotensin receptor blockers (ARB). In this randomized open clinical trial the investigators will study the effect of the blockade of AT1-Ab with losartan in carotid intima-media thickness progression in patients with lupus nephritis compared to patients treated with enalapril.
Timeline
- Start
- 2017-09-10
- Primary completion
- 2019-07-31
- Completion
- 2019-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Enalapril | Other / unclassified | — | — |
| Subject | Losartan | Other / unclassified | — | — |